Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (DE:1VT)
FRANKFURT:1VT
1VT Stock Chart & Stats
€24.54
-€0.26(-0.65%)
At close: 4:00 PM EST
€24.54
-€0.26(-0.65%)
Day’s Range― - ―
52-Week Range€16.40 - €39.10
Previous CloseN/A
Volume0.00
Average Volume (3M)430.00
Market Cap
€2.78B
Enterprise Value€3.04B
Total Cash (Recent Filing)€714.57M
Total Debt (Recent Filing)€755.00K
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding113,036,350
10 Day Avg. Volume560
30 Day Avg. Volume430
Financial Highlights & Ratios
PEG Ratio-3.63
Price to Book (P/B)4.98
Price to Sales (P/S)0.00
P/FCF Ratio-49.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€79.82Price Target Upside225.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Enrollment MomentumStrong enrollment across studies, including full Phase I maintenance enrollment and VANQUISH-1 exceeding targets, signals robust patient demand and supports timely generation of clinical data.
Commercial Leadership And Launch PreparednessAddition of an experienced chief commercial officer with decades in cardiometabolic commercialization strengthens readiness for market entry and strategic go-to-market execution.
Same-molecule Oral-to-injectable StrategyPlanned transition from subcutaneous to oral formulations using the same molecule could enable a seamless patient switch, reducing the risk of new tolerability issues and differentiating the drug commercially.
Bears Say
Analyst Sentiment DependencyAnalyst recommendations are contingent on maintenance trial outcomes, which increases near-term investor uncertainty and potential trading volatility for the stock.
Maintenance Data UncertaintyKey safety and durability endpoints from the maintenance dosing trial remain unreported, leaving the therapy's clinical profile and market potential unclear until those results are available.
Partnership And Acquisition RiskPotential partners or acquirers may postpone strategic decisions until maintenance data confirm tolerability and durability, which could limit near-term deal activity or valuation upside.
Viking Therapeutics News
1VT FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was €16.40 and its highest was €39.09 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is €2.78B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Apr 29, 2026 which is in 75 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Feb 11, 2026. The company reported -€1.161 earnings per share for the quarter, missing the consensus estimate of -€0.755 by -€0.407.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 113,036,350 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -€1.161 in its last earnings report, missing expectations of -€0.755. Following the earnings report the stock price went up 7.51%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in DE:1VT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€79.82 (225.28% Upside)
€79.82 (225.28% Upside)
Blogger Sentiment
Bullish
DE:1VT Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $12.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.01%
12-Months-Change
Fundamentals
Return on Equity
-29.23%
Trailing 12-Months
Asset Growth
-21.16%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
1VT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.View all DE:1VT earnings summaries1VT Stock 12 Month Forecast
Average Price Target
€79.82
▲(225.28% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Options Prices
Currently, No data available
---